Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Presentation

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

November 14, 2019

Presentation JIM 2019

GP IIb/IIIa inhibitors are still the best option

Presenter: Alberto Menozzi

February 15, 2019

Presentation TCT Abstracts Posters 2018

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

Presenter: R. Anantharaman

September 25, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation JIM 2018

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Presenter: Ferdinando Varbella

February 23, 2018

Presentation JIM 2018

Case: Immediate PCI + downstream clopidogrel

Presenter: Giuseppe Tarantini

February 23, 2018

Presentation TTT 2018

Prolonged DAPT should be Standard of Care Post PCI?

Presenter: Tan Huay Cheem

January 14, 2018

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

Presentation

Efficacy, Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing PCI

Presenter: Matteo Bianco

January 20, 2016

Presentation

Aspirin Treatment and Outcomes After PCI

Presenter: Katharina Mayer

August 25, 2014

Presentation PCI Outcomes 2014

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Presenter: Christopher Granger

March 28, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical Outcomes of PCI Performed Without Preprocedural Aspirin

Presenter: M. Kenaan

October 02, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

Presentation ACVS 2012

Which Antiplatelets to Use for PCI?

Presenter: Dev Pahlajani

August 04, 2012

Advertisement

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

GP IIb/IIIa inhibitors are still the best option

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Case: Immediate PCI + downstream clopidogrel

Prolonged DAPT should be Standard of Care Post PCI?

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

Efficacy, Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing PCI

Aspirin Treatment and Outcomes After PCI

Atrial Fibrillation and PCI: Antiplatelet Therapy Recommendations

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical Outcomes of PCI Performed Without Preprocedural Aspirin

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Which Antiplatelets to Use for PCI?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content